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Hepatitis C virus (HCV) contains two membrane-associated envelope glycoproteins, E1 and E2, which
assemble as a heterodimer in the endoplasmic reticulum (ER). In this study, predictive algorithms and genetic
analyses of deletion mutants and glycosylation site variants of the E1 glycoprotein were used to suggest that
the glycoprotein can adopt two topologies in the ER membrane: the conventional type I membrane topology and
a polytopic topology in which the protein spans the ER membrane twice with an intervening cytoplasmic loop
(amino acid residues 288 to 360). We also demonstrate that the E1 glycoprotein is able to associate with the
HCV core protein, but only upon oligomerization of the core protein in the presence of tRNA to form capsid-like
structures. Yeast two-hybrid and immunoprecipitation analyses reveal that oligomerization of the core protein
is promoted by amino acid residues 72 to 91 in the core. Furthermore, the association between the E1
glycoprotein and the assembled core can be recapitulated using a fusion protein containing the putative
cytoplasmic loop of the E1 glycoprotein. This fusion protein is also able to compete with the intact E1
glycoprotein for binding to the core. Mutagenesis of the cytoplasmic loop of E1 was used to define a region of
four amino acids (residues 312 to 315) that is important for interaction with the assembled HCV core. Taken
together, our studies suggest that interaction between the self-oligomerized HCV core and the E1 glycoprotein
is mediated through the cytoplasmic loop present in a polytopic form of the E1 glycoprotein.
Hepatitis C virus (HCV) is the causative agent of chronic
hepatitis C, leading to steatosis, cirrhosis, and hepatocellular
carcinoma. It is estimated that over 170 million people are
infected with HCV worldwide (5, 18, 37). HCV is an enveloped
single-stranded plus-sense RNA virus in the Hepacivirus genus
of the family Flaviviridae, which also includes the flaviviruses
and pestiviruses (36). The genome of HCV encodes a polyprotein of approximately 3,000 amino acids which is cotranslationally and posttranslationally processed to generate at least 10
viral proteins (12). The structural proteins, the core and E1
and E2 envelope glycoproteins, are encoded in the N-terminal
portion of the polyprotein, and the nonstructural proteins,
thought to be required for replication of the viral genome, are
encoded in the C-terminal region (11). The core protein, which
interacts with viral RNA (47) to form the nucleocapsid, is
liberated from the N terminus of the polyprotein by signal
peptidase cleavage in the downstream E1 protein (at position
191), and the C-terminal transmembrane region of the core
protein (residue 164 to 191) is further cleaved at residues 177
or 179 by the signal peptide peptidase (16, 43). The remaining
hydrophobic region of the core protein (domain II; residues
119 to 174) has been shown to affect the efficiency of signal
peptide peptidase cleavage and the intracellular localization of
core protein (14, 44). Although the C-terminal transmembrane
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region of core protein and E1 were reported to interact with
each other within the intramembrane space (25), the central
hydrophobic region from residues 119 to 152 within domain II
was also suggested to be responsible for the interaction between core and E1 (27).
Recently, in vitro replication of a JFH1 clone of HCV genotype 2a derived from a patient with fulminant hepatitis C
was reported in a cell line that had been cured of its HCV
replicon by treatment with interferon (23, 50, 51). However,
this reverse genetics system is limited to the JFH-1 clone of
genotype 2a and specific cell lines. Robust and reliable in vitro
replication of other major genotypes of HCV such as genotypes 1a and 1b has yet to be developed. So far, biological
functions of HCV envelope proteins have been characterized
by using recombinant envelope proteins expressed in vitro,
HCV-like particles produced in insect cells, and the pseudotyped
virions based on vesicular stomatitis virus and retroviruses (8).
The HCV polyprotein precursor must be specifically threaded
through the membrane of the endoplasmic reticulum (ER) to
undergo maturation to form the mature envelope glycoproteins (7). In the polyprotein, the C-terminal regions of E1 and
E2 each contain a membrane-spanning domain as well as the
hydrophobic signal peptide of the downstream viral protein
(E2 and p7, respectively). These domains form hairpin structures that pass through the membrane twice, to allow processing by signal peptidase in the ER lumen. Upon signal peptidase
cleavage, the C termini are thought to translocate into the
cytoplasm to generate the type I membrane topology of the
mature glycoproteins. The mature E1 and E2 glycoproteins
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remain noncovalently associated, interacting in part through
their C-terminal transmembrane domains, which also mediate
retention of the E1-E2 complex in the ER. Based on this
model of membrane topology, the HCV envelope glycoproteins possess little or no cytoplasmic region. However, a physical association between E1 and the cytosolic core protein has
been reported (25, 27), suggesting that the E1 glycoprotein is
able to expose a cytoplasmic domain of sufficient length to
interact with the core. In addition, the presence of the core
protein has been shown to affect the folding of E1 (32).
We have previously suggested that the E1 glycoprotein may
adopt a polytopic (double membrane-spanning) topology that
coexists with the dominant type I form (35). In this study, we
provide genetic evidence for a polytopic form of the E1 glycoprotein and for exposure of a centrally located cytoplasmic
domain. Furthermore, we show that the cytoplasmic region of
the polytopic form of E1 is required for interaction with amino
acid residues 72 to 91 of the core protein.

MATERIALS AND METHODS
Cell culture. 293T cells were maintained in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis, MO) containing 2 mM L-glutamine, penicillin, and
streptomycin and supplemented with 10% fetal bovine serum.
Plasmids. A cDNA of E1 glycoprotein was amplified from HCV type 1b strain
J1 (1) by PCR using Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA) and
inserted between NheI and BamHI sites of pJW4303, which contains the signal
sequence of tissue plasminogen activator and the bovine growth hormone polyadenylation signal (a kind gift from J. M. Mullins), to generate pJW383. For the
deletion analysis, the plasmids pJW360 and pJW288 encoding residues 192 to
360 and 192 to 288, respectively, were amplified by PCR and cloned into
pJW4303. The plasmids pJW383d1 and pJW383d2, containing deletions in residues 261 to 286 and 289 to 340, respectively, were generated from pJW383 by
splicing of overlapping extensions (13, 15) as described previously (44). A cDNA
fragment encoding core to E2 proteins of HCV strain J1 was amplified by PCR
and cloned into pCAGGs-PUR (28), and glycosylation site mutations in the E1
protein were generated by the method of splicing by overlapping extension. For
the yeast two-hybrid assay, pGBKT7HCVCore173 was used as bait, as described
previously (38). The gene encoding amino acids 288 to 346 of HCV E1 protein
was amplified from cDNA of strain J1 and introduced into NdeI and EcoRI sites
of a pGADT7 vector (Clontech, Palo Alto, CA). In the same way, deletion
mutants of core protein encoding residues 1 to 151, 1 to 25, 24 to 173, 38 to 173,
58 to 173, 72 to 173, and 92 to 173 were amplified by PCR and cloned into a
pGBKT7 vector. The FLAG sequence was introduced between amino acids 195
and 196 of the cDNA encoding residues 1 to 383 of the HCV polyprotein and
replaced Ala383 with Arg to avoid processing by signal peptidase and spacer
amino acids (Gly-Gly-Gly-Ser), and influenza virus hemagglutinin (HA) sequence was added at the C terminus. The resulting cDNA fragment encoding
core protein, FLAG tag, E1, and HA tag was cloned into a pcDNA3.1(⫹) vector
and designated Flag-core-E1-HA (see Fig. 2D, below) and used for in vitro
transcription and translation. Similarly, the FLAG sequence was introduced into
the cDNA encoding residues 151 to 383 of the HCV polyprotein, and the HA
sequence was added at the C terminus. The resulting cDNA fragment encoding
the C-terminal hydrophobic/transmembrane region of the core protein, FLAG
tag, E1, and HA tag was designated Flag-E1-HA (see Fig. 3A, below). The DNA
fragments encoding residues 1 to 191 with amino acids 72 to 91 deleted were
generated by splicing via overlapping extension and cloned into pCAGGS
(Core⌬72-91) (see Fig. 4A, below) (42). The DNA fragment encoding the cytoplasmic domain of the E1 protein with a C-terminal HA tag was amplified by
PCR and introduced at HindIII and SacII sites of pEGFP-C3. pCAGGS plasmids encoding core to p7 replacing residues 304 to 307, 308 to 311, 312 to 315,
316 to 319, 320 to 323, 324 to 327, or 328 to 331 with Ala were generated by using
splicing with overlapping extension (see Fig. 6A, below).
Antibodies. Mouse monoclonal antibody to HA tag (HA11) and anti-FLAG
antibody (M2) were purchased from Covance (Richmond, CA) and Sigma,
respectively. Mouse monoclonal antibodies to core protein (clones 11-7, 11-10,
and 11-14) were gifts from S. Yagi (2). Anti-E1 mouse monoclonal antibody
(clone 0726) was prepared by immunization using the membrane fraction of the
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CHO L10 cell line, which constitutively expresses HCV envelope proteins (30).
Anti-E2 monoclonal antibody (clone 187) was a generous gift from M. Kohara.
Yeast two-hybrid assay. A yeast two-hybrid assay was carried out by using
Matchmaker system 3 (Clontech) according to the manufacturer’s protocol. The
bait vector pGBKT7HCVcore 173 (38) or empty plasmid was transfected into
Saccharomyces cerevisiae strain AH109 together with the prey vectors, pGADT7based constructs (see Table 1, below). The yeast cells possessing pGBKT7/p-53
and pGADT7/large T antigen were used as positive controls, while yeast cells
possessing pGBKT7 and pGADT7 were the negative controls. These transfected
yeast colonies were cultivated on dropout plates lacking Trp, Leu, His, and Ade
(test plates) or plates lacking Trp and Leu (control plates) and then incubated at
30°C for 1 week.
Transfection, immunoblotting, and immunoprecipitation. Liposome-mediated DNA transfection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was
described previously (38). Transfected cells were cultured at 2 ⫻ 105 cells/well in
a six-well plate, harvested 30 to 48 h posttransfection, washed twice with phosphate-buffered saline (PBS), and incubated at 4°C for 30 min in 0.25 ml of lysis
buffer (20 mM Tris-HCl [pH 7.4], 135 mM NaCl, 1% Triton X-100, and 10%
glycerol supplemented with 1 mM phenylmethylsulfonyl fluoride, 50 mM NaF,
and 5 mM Na3VO4). After freezing and thawing, lysed cells were centrifuged at
20,000 ⫻ g for 5 min. The resulting cleared lysate was stored at ⫺80°C prior to
use for immunoprecipitation and blotting. Immunoprecipitation was carried out
according to the method described previously (44). Briefly, lysates were preincubated at 4°C for 5 h in the lysis buffer with or without 1 mM MgCl2 and 0.1
mg/ml of yeast tRNA (Sigma) prior to immunoprecipitation. The resulting lysates (0.2 ml) were gently rotated with 1.0 g of anti-FLAG, anti-HA, or mixed
mouse monoclonal anti-HCV core antibodies or mouse monoclonal antibody to
the E1 protein at 4°C for 3 h with or without 1 mM MgCl2 and 0.1 mg/ml of yeast
tRNA. The immunocomplex was gently rotated at 4°C for 3 h with 10 l of 50%
(vol/vol) protein G-Sepharose 4 Fast Flow beads (Amersham Pharmacia Biotech, Franklin Lakes, NJ) with or without 1 mM MgCl2 and 0.1 mg/ml of yeast
tRNA and then centrifuged at 20,000 ⫻ g for 30 s. The precipitated beads were
washed five times with 0.5 ml of lysis buffer containing or lacking 1 mM MgCl2
and 0.1 mg/ml of yeast tRNA and then boiled in 50 l of the loading buffer. The
boiled samples were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The proteins in gels were transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore, Bedford, MA) and then blotted with
primary antibody and secondary horseradish peroxidase-conjugated antibody.
The immunocomplexes on membranes were visualized with Super Signal West
Femto substrate (Pierce, Rockford, IL) and detected by using an image analyzer
LAS-3000 (Fujifilm, Tokyo, Japan).
Protease protection assay of HCV proteins synthesized by in vitro transcription/translation. A plasmid encoding a FLAG-core-E1-HA protein was transcribed under the control of a T7 promoter by using the RiboMax large-scale
RNA production system with Ribo m7G cap analog (Promega, Madison, WI). In
vitro translation was carried out in the presence of [35S]methionine-cysteine
(Amersham, Piscataway, NJ) by using rabbit reticulocyte lysate and canine pancreatic microsomal membrane (Promega). Translated sample was diluted sevenfold with PBS and then mixed with tosylsulfonyl phenylalanyl chloromethyl
ketone-treated trypsin (Sigma) at a final concentration of 2 g/ml. The mixture
was incubated at 30°C for 60 min with or without 0.5% Nonidet P-40, and then
soybean trypsin inhibitor (Sigma) was added at a final concentration of 20 g/ml.
Digestion products were immunoprecipitated with anti-FLAG antibody.
Indirect immunofluorescence analysis. 293T cells were washed with PBS at
40 h after transfection and fixed with 3% paraformaldehyde in PBS for 20 min at
room temperature. The fixed cells were permeabilized with 0.2% Triton X-100
for 3 min at room temperature and blocked with nonfat milk solution. Cells were
incubated with the anti-E1 antibody for 60 min at 37°C and then with fluorescein
isothiocyanate-conjugated goat anti-mouse immunoglobulin G (IgG; TAGO,
Burlingame, CA). HCV E1 protein was visualized by fluorescence microscopy
(TE300; Nikon, Tokyo, Japan).
Velocity sedimentation with sucrose gradients. Transfected 293T cell were
suspended in MNT buffer (20 mM 2-morpholinoethanesulfonic acid, 100 mM
NaCl, 30 mM Tris-HCl [pH 8.6], and 0.1% Triton X-100) and then incubated at
4°C for 5 h with or without 0.1 mg/ml of yeast tRNA and 1 mM MgCl2. Each
sample was layered on top of 12 ml of sucrose with a 20 to 60% gradient and then
centrifuged in a Beckman SW 41Ti rotor (Beckman Coulter, Tokyo, Japan) at
30,000 rpm for 3 h at 4°C. Centrifuged lysates were collected from the
bottoms of the tubes and then concentrated with trichloroacetic acid. After
washing with ethanol, concentrated proteins were subjected to SDS-PAGE
and immunoblotting.
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RESULTS
Prediction of the topology of the E1 protein in the membrane. Although a small fraction of the HCV envelope glycoproteins expressed in 293T cells is translocated onto the
plasma membrane (3), the vast majority of E1 is retained in the
ER membrane (6). Previously, we showed that both a central
hydrophobic region of E1 (residues 260 to 288) and the Cterminal transmembrane domain (residues 360 to 383) are
important for ER retention (29). As in the C-terminal hydrophobic region, the amino acid sequence of the central hydrophobic region is highly conserved among HCV isolates (4). To
investigate the role of these two hydrophobic regions in the
biogenesis of the E1 glycoprotein, we utilized the TMHMM
algorithm (19), a computer program trained to identify potential transmembrane helical regions. The algorithm identified
both hydrophobic regions as having a high probability of transmembrane helix (Fig. 1A). To examine the function of the
hydrophobic regions as transmembrane domains, we constructed a series of deletion mutants in the E1 protein in which
one or the other of the hydrophobic segments was absent (Fig.
1B). Mutant E1 glycoproteins were expressed in 293T cells,
and the cellular localization of E1 proteins was determined by
indirect immunofluorescence analysis (Fig. 1B). The fulllength E1 (383) was detected only in permeabilized cells, consistent with its retention in the ER. The 383d2 mutant, which
contains both hydrophobic regions but lacks the intervening
hydrophilic region (residues 289 to 340), was also detected in
the cytoplasm but not on the cell surface as the full-length E1.
By contrast, deletion mutants lacking the central (383d1) or
C-terminal (288 and 360) hydrophobic domains were detected
on the cell surface in nonpermeabilized cells, suggesting that
both the central and the C-terminal hydrophobic domains are
required for retention of the E1 protein on the ER membrane.
If the central hydrophobic domain traverses the ER membrane
as predicted by the TMHMM program, the region between
positions 288 and 360 would be expected to lie in the cytoplasmic space. Based on this model and on the results with E1
deletion mutants, we suggest that the E1 protein might be able
to retain two membrane topologies: the conventional type I
topology and a polytopic topology that spans the membrane
twice with N and C termini in the ER lumen and an intervening
cytoplasmic loop, as reported previously (35) (Fig. 1C). Recently, a similar polytopic form of the fusion glycoprotein of
Newcastle disease virus was identified (31).
Mutational analysis of putative N-glycosylation sites of the
E1 glycoprotein. To explore the membrane topologies of E1,
we examined the utilization of potential glycosylation sites.
The E1 protein of HCV strain J1 (1) contains seven N-glycosylation sequence motifs (Asn-X-Ser/Thr) at amino acid positions 196, 209, 233, 234, 250, 305, and 325 (Fig. 2A). The Asn
residues at these possible N-glycosylation sites were individually replaced with Gln, and the mutant E1 glycoproteins were
expressed as a core-, E1-, or E2-containing polyprotein in 293T
cells. In all cases, the mutant polyproteins were expressed and
properly processed by signal peptidase and signal peptide peptidase to generate the core, E1, and E2 proteins (Fig. 2B). The
mutant E1 proteins displayed distinct glycoforms consistent
with changes in glycosylation. The wild-type E1 glycoprotein
exhibited a major band of 34 kDa and a minor band of 32 kDa.

FIG. 1. Prediction of the membrane topology of the E1 protein.
(A) Genome structure of HCV and a hydrophobic profile of the amino
acid sequence of the E1 protein are shown at the top. The transmembrane helices in the E1 protein were predicted by the TMHMM program (19), and regions of high probability (amino acid residues 265 to
287 and 358 to 377) are indicated. (B) 293T cells transfected with the
wild type (383) and deletion constructs were fixed with paraformaldehyde and permeabilized with Triton X-100 (intracellular) or not permeabilized (surface). E1 proteins were visualized with an anti-E1
monoclonal antibody and fluorescein isothiocyanate-conjugated antimouse IgG. (C) Possible topologies of the E1 protein on the ER.
(Left) Type I topology model possessing a C-terminal transmembrane
region; (right) a polytopic topology that spans the membrane twice,
with both N and C termini in the ER lumen and with an intervening
cytoplasmic loop.

The 325 mutant was unchanged from the wild-type E1, suggesting that the 325 position is not utilized, presumably due to
an unfavorable NWSP motif in the genotype 1a protein (33).
The 209, 233/234, and 250 mutants migrated faster than the
authentic E1 protein and exhibited two bands of 32 and 30
kDa. The E1 of the 196 mutant was apparently not recognized
by the monoclonal antibody directed to the N-terminal region
of E1. In the 233 and 234 mutants, glycosylation occurred at
the remaining Asn (234 or 233, respectively). These mutants
comigrated with the wild-type E1 glycoforms, suggesting that
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FIG. 2. Mutational analysis of N-glycosylation sites and protease protection assay of the E1 protein. (A) Positions of potential N-glycosylation
sites (gray and black spikes) in the E1 protein are shown. (B) Asn residues
in the possible N-glycosylation sites in the E1 protein were individually
replaced with Gln. Mutant plasmids encoding the core, E1, and E2
polyproteins (A) were expressed in 293T cells, and processed core, E1,
and E2 proteins were detected by immunoblotting. (C) Type I and polytopic topology models of E1 proteins bearing carbohydrates at positions
of 196, 209, 234, 250, and 305 (5G) and 196, 209, 234, and 250 (4G),
respectively. The 305 mutant would exhibit a single band of 4G irrespective of
the topologic models. (D) Structure of the FLAG-core-E1-HA construct
encoding the HCV core and E1 polyprotein carrying FLAG and HA tags in
the N- and C-terminal regions of the E1 protein (top). (Bottom, left) In vitro
translation of capped RNA transcribed from the FLAG-core-E1-HA (lane 2)
and without RNA (lane 1) in the presence of [35S]methionine-cysteine using
rabbit reticulocyte lysate and canine pancreatic microsomal membrane. (Bottom, middle) Translated products of FLAG-core-E1-HA (lane 2) and without RNA (lane 1) were digested with trypsin in the presence (⫹) or absence
(⫺) of 0.5% Nonidet P-40. (Bottom, right) Digestion products were immunoprecipitated with control (lane 1) and anti-FLAG (lane 2) antibody. Black
and white arrows indicate protected and digested E1 protein, respectively.

J. VIROL.

only one or the other of the overlapping motifs can be utilized
in the wild-type molecule. Glycosylation in this region was
absent in the double mutant (233/234). The existence of two
glycoforms of E1 may reflect incomplete and stochastic use of
the available glycosylation sites or, alternatively, the presence
of two discrete topological forms of E1 protein. For instance,
the major band of 34 kDa in the wild-type glycoprotein might
correspond to the type I topology form, with glycosylation at
196, 209, 234, 250, and 305 (5G), whereas the minor band of 32
kDa might correspond to the polytopic form of E1, bearing
glycans at positions 196, 209, 234, and 250 (4G). In this regard,
it is noteworthy that the 305 mutant of E1 exhibited only a
single band of 32 kDa. The absence of a second glycoform is
consistent with the putative cytoplasmic localization of Asn305
in a polytopic form of E1 (Fig. 2C). Taken together, this
mutational analysis provides support to the model in which the
HCV E1 glycoprotein is able to exist in either the type I or
polytopic form. In the latter form, an extended cytoplasmic
domain in E1 would be available to interact with the core
protein in the virion.
Protease protection assay of the E1 protein. To confirm the
presence of the cytoplasmic domain in the E1 protein, in vitro
translation products of the HCV core and E1 polyprotein carrying FLAG and HA tags in the N- and C-terminal regions of
the E1 protein, respectively, were digested with trypsin, and
the protected portion of the E1 glycoprotein was immunoprecipitated by anti-FLAG antibody. As shown below in Fig. 4D,
treatment of the translation products with trypsin in the presence of Nonidet P-40 resulted in complete digestion, and a
22-kDa band (major) and several ⬍35-kDa faint bands were
detected in the absence of the detergent. When in vitro-translated HCV core protein was treated similarly, no band was
detected, irrespective of the presence of detergent (data not
shown); therefore, the protected bands from trypsin digestion
were derived from the E1 protein. Although the 22- to 35-kDa
bands were specifically immunoprecipitated with anti-FLAG
antibody but not with control antibody, the 35-kDa protein
corresponding to the type I topology of the E1 protein resistant
to trypsin digestion was dominant. This might be due to the
difference in the reactivity of the anti-FLAG antibody, which
recognizes the intact E1 protein more efficiently than digested
ones. These results further support the presence of the polytopic form of HCV E1 glycoprotein, which has a cytoplasmic
region together with a type I topology in the ER.
HCV core protein binds to the E1 protein in the presence of
tRNA. The HCV core protein undergoes extensive conformational changes upon binding to nucleic acid and self-assembling into nucleocapsid-like particles (20). To investigate the
effects of nucleic acid on oligomerization of the core protein,
lysates of 293T cells expressing HCV core protein were incubated in the presence or absence of yeast tRNA (20) and
subjected to velocity sedimentation in a sucrose gradient.
Oligomerized core protein was detected in fractions 1 to 4 in
the presence of tRNA but not in those in the absence of tRNA
(Fig. 3A). To specifically examine the interaction between
HCV core and E1 proteins in the assembly of the nucleocapsid-like particles, we coexpressed the core protein with an E1
protein possessing a FLAG tag near its N terminus and an HA
tag at the C terminus (Flag-E1-HA) (Fig. 3B, left). The transfected cells were lysed with Triton X-100, and the E1 protein
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FIG. 3. HCV core protein binds to E1 protein in the presence of
tRNA. (A) Cell lysates of 293T cells expressing HCV core protein
were subjected to velocity sedimentation with a sucrose gradient in the
presence or absence of tRNA. Oligomerized core protein was detected
in fractions 1 to 4 in the presence of tRNA but not in those in the
absence of tRNA. (B, left) cDNAs used for expression. FLAG-E1-HA
encodes FLAG tag after the signal peptide and HA tag after the
transmembrane region. (Right) Immunoprecipitation analyses. Cell
lysates of 293T cells expressing core and FLAG-E1-HA proteins were
immunoprecipitated by anti-FLAG antibody in the presence or absence of tRNA. The asterisks indicate nonspecific bands.

was immunoprecipitated by using an anti-FLAG antibody. Coprecipitation of core protein with E1 was assessed by Western
blot analysis using a core-specific monoclonal antibody. Although HCV core protein was clearly coprecipitated with
FLAG-E1-HA in the presence of tRNA, little association was
seen in the absence of tRNA (Fig. 3B, right). Nonspecific
precipitation of the core protein with tRNA was not observed
(data not shown). Although a small amount of the intracellular
core protein may already associate with viral RNA under the
intracellular conditions, a large amount of RNA may be required for oligomerization that is detectable by the sedimentation assay. Together, our results suggest that tRNA facilitates oligomerization of the HCV core protein and potentiates
the interaction between the core protein and E1.
The region spanning amino acid residues 72 to 91 in the
HCV core protein is crucial for binding to the E1 protein in
yeast. The interaction between the HCV core and E1 proteins
likely occurs on the cytosolic side of the cell membrane and,
thus, presumably involves the posited cytoplasmic loop region
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in the polytopic form of the E1 glycoprotein. To investigate the
possibility for this specific interaction in cells, core protein
lacking the transmembrane region (Core1-173) was examined
for interaction with the putative E1 cytoplasmic loop region in
a yeast two-hybrid system (Table 1). When Core1-173 was
expressed with the E1 cytoplasmic region (residues 288 to 346),
the yeast was able to grow on the dropout plate lacking Trp,
Leu, His, and Ade, suggesting that the core protein associates
with the cytoplasmic loop of the E1 protein in yeast. To determine the region of the HCV core protein responsible for the
interaction with the cytoplasmic domain of E1, deletion mutants of the core were tested. Association in the yeast twohybrid system was seen with Core24-173, Core38-173, Core58173, Core72-173, and Core1-151 mutants, but not with Core92173 and Core1-25. Nonspecific interaction of the GAL4
activation domain with these core mutants was not observed.
These results suggest that the region spanning from amino acid
residues 72 to 91 in the HCV core protein is important for
interaction with the cytoplasmic domain of the E1 protein in
yeast.
Amino acid residues 72 to 91 in the core protein are involved
in oligomerization of the core protein and interaction with the
E1 protein in mammalian cells. To examine the involvement
of amino acid residues 72 to 91 of the HCV core protein in the
interaction with the E1 protein in mammalian cells, FLAGE1-HA was coexpressed with either a wild-type core or a deletion mutant lacking amino acid residues 72 to 91 (Core⌬7291) in 293T cells (Fig. 4A). Cell lysates were incubated with
yeast tRNA, and FLAG-E1-HA was immunoprecipitated with
anti-FLAG antibody. As shown in Fig. 4B (left), only the wildtype core protein, but not Core⌬72-91, coprecipitated with E1.
Self-oligomerization was also prevented by the deletion in
Core⌬72-91 (Fig. 4B, right). These results suggest that amino
acid residues 72 to 91 in the HCV core protein play a crucial
role in the interaction with the E1 protein and oligomerization
of the core protein.
The E1 cytoplasmic domain interacts with the core protein
in mammalian cells and inhibits the interaction with intact E1
protein in trans. To assess the involvement of the E1 cytoplasmic region in the interaction with core protein in mammalian

TABLE 1. Interaction between the core and the E1 cytoplasmic
region in yeast
Growth with prey a
Bait

Core1-173
Core24-173
Core38-173
Core58-173
Core72-173
Core92-173
Core1-151
Core1-25
No insert

E1 cytoplasmic loop

No insert

Dropout

Control

Dropout

Control

ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴚ
ⴙ
ⴚ
ⴚ

ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ

ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ

ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ
ⴙ

a
HCV core mutants were expressed as fusion proteins with the DNA binding
region by using a bait plasmid. The HCV E1 cytoplasm region was expressed as
a fusion protein with an activation domain by using a prey plasmid. Yeast growth
was observed in dropout plates lacking Trp, Leu, Ade, and His (dropout) or
plates lacking Trp and Leu (control). ⫹, growth; ⴚ, no growth.
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FIG. 4. Amino acid residues72 to 91 in the core protein are involved in oligomerization of the core protein and interaction with the
E1 protein. (A) cDNAs used for expression. Core⌬72-91 is an HCV
core protein carrying a deletion of amino acid residues 72 to 91. (B,
left) FLAG-E1-HA was coexpressed in 293T cells with either a wildtype core or Core⌬72-91, and the interaction was analyzed by immunoprecipitation in the presence of tRNA. The asterisks indicate nonspecific bands. (Right) Oligomerization of a wild-type core or
Core⌬72-91 in the presence of tRNA. Wild-type core protein was
self-oligomerized, but Core⌬72-91 was not.

cells, we constructed an enhanced green fluorescent protein
(EGFP) fusion protein carrying the E1 cytoplasmic domain
followed by an HA tag (EGFP-cdE1-HA) (Fig. 5A). Upon
coexpression of EGFP-cdE1-HA with the wild-type core protein in 293T cells, the two proteins could be coprecipitated
using anti-HA antibody (Fig. 5B). The mutant Core⌬72-91
protein was unable to associate with EGFP-cdE1-HA (Fig.
5B). Together, these studies demonstrate that the cytoplasmic
loop region of E1 is able to interact with the core protein and
that core residues 72 to 91 are required for this association.
To further confirm the specificity of the interaction of the E1
cytoplasmic region with the core protein, we examined the
ability of the EGFP-cdE1-HA protein to inhibit the association
of the intact E1 protein (in Flag-E1-HA) with the wild-type
core protein (Fig. 5C). Expression of EGFP-cdE1-HA but not
EGFP-HA competed strongly with the interaction between
core and the FLAG-tagged Flag-E1-HA protein. These results
suggest that the cytoplasmic loop in the intact E1 glycoprotein
can directly bind to HCV core protein. Interestingly, the
EGFP-cdE1-HA protein was unable to inhibit this interaction
in the context of the intact core and E1 and E2 polyproteins
(data not shown), suggesting that expression of the core and
E1 proteins in cis may prevent subsequent interaction with E1
expressed in trans.

FIG. 5. Interaction of the E1 cytoplasmic loop with the core protein. (A) cDNAs used for expression. EGFP-cdE1-HA is an EGFP
fusion protein carrying the E1 cytoplasmic region of amino acid residues 288 to 346 followed by an HA tag. (B) Wild-type core or
Core⌬72-91 was coexpressed with EGFP-cdE1-HA in 293T cells, and
their interaction was analyzed by immunoprecipitation. EGFPcdE1-HA coprecipitated with wild-type core protein, but not with
Core⌬72-91. (C) Inhibition of the interaction of the core protein with
FLAG-E1-HA by expression of EGFP-cdE1-HA. Expression of
EGFP-cdE1-HA but not of EGFP disrupted the interaction between
core and E1 proteins.

Four amino acid residues, 312 to 315, in the cytoplasmic
region of the E1 protein are important for interaction with the
core protein. Alignment of the amino acid sequence of the E1
cytoplasmic region among different HCV genotypes revealed
that the region from Gln302 to Pro328 is highly conserved (Fig.
6A). To determine residues in the E1 cytoplasmic region that
are critical for interaction with the core protein, blocks of four
residues each in the conserved region were replaced with Ala
in the polyprotein (core, E1, E2, and p7) (Fig. 6A). These
mutant polyproteins were expressed in 293T cells and immunoprecipitated with anti-core antibody; coprecipitated E1 protein was detected by immunoblotting using an anti-E1 monoclonal antibody (Fig. 6B). The replacement of four amino acid
residues, 304 to 307, with Ala in the conserved region of the E1
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FIG. 6. Four amino acid residues, 312 to 315, in the cytoplasmic
region of the E1 protein are important for interaction with the core
protein. (A) Alignment of the amino acid sequence of the E1 cytoplasmic region among different HCV genotypes (1a, H77 [AF009606];
1b, J1 [D89815]; 2a, JFH1 [AB047639]; 3a, CB [AF046866]; 4a, ED43
[Y11604]; 5a, EUH1480 [Y13184]). A conserved region from Gln302 to
Pro328 is shown by gray shading. Mutant polyproteins consisting of the
core, E1, E2, and p7 proteins with four residues each replaced by Ala
in the conserved E1 region were constructed. Four amino acid residues, His312, Val313, Ser314, and Gly315, in the E1 cytoplasmic region of
strain J1 and substitution of the amino acids with Ala in Cp7 (312315A) are indicated by the box. (B) These mutant polyproteins were
expressed in 293T cells and immunoprecipitated with anti-core antibody or nonspecific mouse IgG in the presence of MgCl2 and tRNA.
The E1 protein that coprecipitated with the core protein was detected
by immunoblotting. The substitution of four amino acid residues, 304
to 307, with Ala in the conserved region of the E1 protein, Cp7
(304-307A), could not be examined due to the low level of expression.

protein could not be examined due to a low level of expression
(data not shown). Among the mutant constructs examined,
only the substitution at residues 312 to 315, Cp7 (312-315A),
markedly diminished association with the core protein (Fig.
6B). These results suggest that this region in the E1 cytoplasmic domain of the J1 strain of HCV (His312, Val313, Ser314, and
Gly315) is important for interaction with the core protein.
DISCUSSION
The biogenesis of the transmembrane glycoproteins involves
a series of coordinated translation and membrane integration
events that are directed by topogenic determinants within the
nascent chains and that ultimately lead to the most favored
topology for any given polypeptide (24). However, there is an
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increasing number of examples of glycoproteins that can assume multiple topological orientations. The large envelope
protein of the hepatitis B virus, for instance, has been suggested to adopt distinct topologies that enable the protein to
serve in virus assembly as a matrix-like protein and in virus
entry as a receptor binding protein (22). An unglycosylated
form of the HCV E2 protein has been identified and shown to
interact with protein kinase R in the cytosol (45). In Newcastle
disease virus, type I and polytopic forms of the fusion protein
are present in the same cell, and the polytopic form is suggested to be involved in the membrane fusion event (31).
HCV glycoproteins E1 and E2 were shown to possess transmembrane domains and associate to form noncovalent heterodimers that are statically retained in the ER membrane
upon recombinant expression (10, 29, 46). Previously, the E1
protein of genotype 1a was suggested to possess a single Cterminal transmembrane domain, based in part on its utilization of potential glycosylation sites (33) and on a model of the
transmembrane domains of the E1 and E2 proteins, in which
the C terminus reorients, upon signal peptidase cleavage, from
the ER lumen to protrude slightly into the cytoplasm (7). In
our study, we have suggested that the E1 protein can also
adopt a polytopic topology in which the protein spans the ER
membrane twice and includes an intervening cytoplasmic region. In this model, the membrane orientation of the C-terminal transmembrane region is inverted and translocation of the
signal peptidase-cleaved C terminus is not required.
Our analysis revealed that the 305 mutant of the 1b genotype
expressed by transfection exhibited a single band of 32 kDa,
whereas that of genotype 1a expressed by recombinant vaccinia
viruses has been reported to contain two bands (33). Although
we do not know the reason for this discrepancy, it may relate
to differences in the expression systems. HCV proteins expressed by vaccinia virus and Sindbis virus vectors formed
disulfide-linked aggregates (9, 11, 34), and coexpression of a
large amount of vaccinia viral proteins also may alter the
proper processing of the expressed proteins, as suggested by
Merola et al. (32). However, further work will be necessary to
clarify the reasons for the differences in glycosylation patterns
of E1 mutants obtained in the different expression systems.
Mottola et al. analyzed the determinants for ER localization
of the E1 protein and showed that the juxtamembrane region of
E1, between amino acid residues 290 and 333, was required for
ER retention (41). This region lies within the ectodomain of
the E1 protein in the type I topology and in the cytoplasmic
region of the protein in the proposed polytopic form. ER
localization determinants of transmembrane proteins have in
general been located either in the cytosolic or in the transmembrane domain, not in the luminal ectodomain, except for
the yeast Sec20 protein (41). Therefore, assignment of the ER
localization signal to the cytoplasmic region of the E1 protein
might further support the possibility of the polytopic topology
model. Affinity purification and membrane reconstitution of
the E1 protein carrying an affinity tag (S-peptide) in the putative cytoplasmic region are also consistent with this model (35).
Together, these findings provide indirect support that the E1
glycoprotein can adopt a polytopic form.
As previously reported (20), oligomerization of the HCV
core protein to form nucleocapsid-like particles requires the
presence of stem-loop RNA structures, such as those in tRNA.
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Here, we have demonstrated that self-assembly of the core
protein occurs without envelope protein in the presence of
tRNA and that tRNA is required for the association of E1
glycoprotein with the core protein, suggesting that oligomerization of the core protein may be a prerequisite for this interaction during virus assembly. Based on hydrophobicity and
the clustering of basic amino acids, the HCV core protein is
proposed to possess three domains: the N-terminal basic and
hydrophilic region (domain 1; residues 1 to 118), a central
basic and hydrophobic domain (domain 2; residues 119 to 174),
and the hydrophobic signal sequence for E1 (domain 3; residues 175 to 191) (14). Biophysical characterization of the core
protein indicated that the C-terminal residues 125 to 179 were
critical for the folding and oligomerization of the core protein
(21). Although our mutant HCV polyprotein containing Ala
substitutions at residues 312 to 315 in the cytoplasmic region of
the E1 protein exhibited a clear reduction in its interaction
with the core protein, a substantial amount of residual binding
was retained. These results suggest that regions other than the
residues from 312 to 315 in the E1 protein are also involved in
the interaction with the core protein.
In Semliki Forest virus, the cytoplasmic domain of the E2
glycoprotein, which corresponds to the E1 protein in HCV, has
been shown to interact with the capsid protein (26, 49). Assembly of alphaviruses has also been found to require the
specific interaction between the C-terminal cytoplasmic domain of the E2 protein and the capsid protein (17). Although
the functional significance of the two forms of the HCV E1
protein is still unclear, the E1 cytoplasmic region among different HCV genotypes is well conserved and four amino acid
residues, His312, Val313, Ser314, and Gly315 of strain J1, were
shown to be important for interaction with the core protein.
Although the four amino acid sequences identified in strain J1
of genotype 1b are not strictly conserved among the different
HCV genotypes (Fig. 6A), a pattern of polar-hydrophobicpolar-glycine residues can be discerned in all of them. The
interaction of the cytoplasmic E1 protein with the core protein
may indicate that the polytopic form is a mature E1 protein
that is incorporated into virions.
In conclusion, the polytopic topology model of the HCV E1
protein and the interaction of oligomerized core protein with
the cytoplasmic region of the E1 protein may provide clues to
aid in understanding the biosynthesis and assembly of the
HCV structural proteins. HCV core protein is also involved in
the development of liver steatosis, type II diabetes mellitus,
and hepatocellular carcinoma in transgenic mice (39, 40, 48). A
detailed knowledge of the assembly of HCV particles will provide the basis for the development of effective therapeutics for
chronic hepatitis C.
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